Al Hammadi Holding Valuation
Is 4007 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
5/6Valuation Score 5/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 4007 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 4007 (SAR39.9) is trading below our estimate of fair value (SAR41.54)
Significantly Below Fair Value: 4007 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 4007?
Key metric: As 4007 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is 4007's PE Ratio? | |
|---|---|
| PE Ratio | 18.3x |
| Earnings | ر.س348.69m |
| Market Cap | ر.س6.38b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 5.5x |
| Enterprise Value/EBITDA | 16.3x |
| PEG Ratio | 2.2x |
Price to Earnings Ratio vs Peers
How does 4007's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 32.8x | ||
4005 National Medical Care | 24.1x | 11.20% | ر.س7.2b |
4009 Middle East Healthcare | 15.1x | 6.29% | ر.س5.9b |
4018 Almoosa Health | 55.1x | 25.65% | ر.س7.2b |
4017 Dr. Soliman Abdel Kader Fakeeh Hospital | 37.1x | 16.47% | ر.س10.7b |
4007 Al Hammadi Holding | 18.3x | 8.27% | ر.س6.4b |
Price-To-Earnings vs Peers: 4007 is good value based on its Price-To-Earnings Ratio (18.3x) compared to the peer average (32.8x).
Price to Earnings Ratio vs Industry
How does 4007's PE Ratio compare vs other companies in the SA Healthcare Industry?
| 0 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|
| 0 Companies | Estimated Growth | Market Cap |
|---|
Price-To-Earnings vs Industry: 4007 is good value based on its Price-To-Earnings Ratio (18.3x) compared to the SA Healthcare industry average (25.4x).
Price to Earnings Ratio vs Fair Ratio
What is 4007's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 18.3x |
| Fair PE Ratio | 20.8x |
Price-To-Earnings vs Fair Ratio: 4007 is good value based on its Price-To-Earnings Ratio (18.3x) compared to the estimated Fair Price-To-Earnings Ratio (20.8x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | ر.س39.90 | ر.س48.19 +20.77% | 9.46% | ر.س55.00 | ر.س42.00 | n/a | 9 |
| May ’26 | ر.س40.10 | ر.س48.19 +20.17% | 9.46% | ر.س55.00 | ر.س42.00 | n/a | 9 |
| Apr ’26 | ر.س41.65 | ر.س49.91 +19.83% | 9.05% | ر.س55.00 | ر.س44.00 | n/a | 9 |
| Mar ’26 | ر.س43.30 | ر.س52.13 +20.40% | 9.19% | ر.س61.00 | ر.س45.00 | n/a | 9 |
| Feb ’26 | ر.س44.10 | ر.س52.13 +18.22% | 9.19% | ر.س61.00 | ر.س45.00 | n/a | 9 |
| Jan ’26 | ر.س38.60 | ر.س52.66 +36.44% | 8.41% | ر.س61.00 | ر.س45.00 | n/a | 9 |
| Dec ’25 | ر.س40.35 | ر.س53.00 +31.35% | 7.41% | ر.س61.00 | ر.س48.00 | n/a | 9 |
| Nov ’25 | ر.س39.95 | ر.س53.00 +32.66% | 7.41% | ر.س61.00 | ر.س48.00 | n/a | 9 |
| Oct ’25 | ر.س42.55 | ر.س53.00 +24.55% | 7.41% | ر.س61.00 | ر.س48.00 | n/a | 9 |
| Sep ’25 | ر.س44.90 | ر.س53.87 +19.98% | 6.81% | ر.س61.00 | ر.س48.00 | n/a | 8 |
| Aug ’25 | ر.س46.05 | ر.س57.65 +25.19% | 6.52% | ر.س64.00 | ر.س54.00 | n/a | 8 |
| Jul ’25 | ر.س45.80 | ر.س57.69 +25.96% | 6.14% | ر.س64.00 | ر.س54.00 | n/a | 9 |
| Jun ’25 | ر.س48.25 | ر.س59.53 +23.37% | 6.88% | ر.س66.00 | ر.س54.00 | n/a | 8 |
| May ’25 | ر.س56.30 | ر.س59.36 +5.43% | 8.99% | ر.س68.00 | ر.س52.00 | ر.س40.10 | 9 |
| Apr ’25 | ر.س56.90 | ر.س60.02 +5.49% | 8.60% | ر.س68.00 | ر.س52.00 | ر.س41.65 | 9 |
| Mar ’25 | ر.س66.90 | ر.س60.63 -9.38% | 8.53% | ر.س68.00 | ر.س52.00 | ر.س43.30 | 8 |
| Feb ’25 | ر.س61.80 | ر.س57.75 -6.55% | 6.29% | ر.س64.00 | ر.س52.00 | ر.س44.10 | 8 |
| Jan ’25 | ر.س60.20 | ر.س57.00 -5.32% | 8.90% | ر.س64.00 | ر.س46.00 | ر.س38.60 | 8 |
| Dec ’24 | ر.س57.00 | ر.س55.75 -2.19% | 8.45% | ر.س61.00 | ر.س46.00 | ر.س40.35 | 8 |
| Nov ’24 | ر.س52.90 | ر.س56.75 +7.28% | 13.38% | ر.س73.00 | ر.س45.00 | ر.س39.95 | 8 |
| Oct ’24 | ر.س53.00 | ر.س56.86 +7.28% | 14.02% | ر.س73.00 | ر.س45.00 | ر.س42.55 | 7 |
| Sep ’24 | ر.س53.80 | ر.س56.63 +5.25% | 13.21% | ر.س73.00 | ر.س45.00 | ر.س44.90 | 8 |
| Aug ’24 | ر.س59.00 | ر.س54.31 -7.94% | 17.16% | ر.س73.00 | ر.س42.00 | ر.س46.05 | 7 |
| Jul ’24 | n/a | ر.س54.31 0% | 17.16% | ر.س73.00 | ر.س42.00 | ر.س45.80 | 7 |
| Jun ’24 | ر.س52.20 | ر.س50.49 -3.27% | 11.77% | ر.س58.00 | ر.س42.00 | ر.س48.25 | 7 |
| May ’24 | ر.س53.80 | ر.س50.06 -6.94% | 10.94% | ر.س55.00 | ر.س42.00 | ر.س56.30 | 7 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/14 16:45 |
| End of Day Share Price | 2025/05/14 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Al Hammadi Holding Company is covered by 15 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jassim Al-Jubran | Aljazira Capital Company |
| Madhu Appissa | Al Rajhi Capital |
| Christine Kalindjian | Arqaam Capital Research Offshore S.A.L. |